Literature DB >> 6426577

Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy.

S H Ralston, I Fogelman, M D Gardiner, I T Boyle.   

Abstract

Some relations between metastatic bone disease and calcium homoeostasis were determined in a consecutive series of 81 patients with solid malignant tumours attending for radionuclide bone scans. Biochemical evaluation showed that bone resorption from metastatic disease was generally not enough to account for hypercalcaemia. While skeletal metastases were present in about half of the patients who developed hypercalcaemia, biochemical indices of bone resorption in these subjects were greatly increased and disproportionate to the extent of metastatic disease detected by the bone scans. Furthermore, a reduced renal phosphate threshold and increased tubular calcium reabsorption were generally observed in hypercalcaemic patients when compared with their normocalcaemic counterparts. These findings suggest that in most cases malignancy associated hypercalcaemia may be caused by the release of a humoral factor by tumour tissue which exhibits "parathyroid-hormone-like" activity with regard to bone resorption, renal phosphate threshold, and renal calcium handling. It may be postulated that this putative humoral mediator predisposes to hypercalcaemia both by stimulating generalised osteolysis and in most cases also by impairing the renal excretion of the resultant increase in filtered calcium load. While hypercalcaemia may arise as a result of metastatic bone disease alone, these data indicate that this may be the exception rather than the rule. Hence the term "metastatic hypercalcaemia" should probably be reserved for patients with extensive skeletal tumour disease in whom biochemical evaluation fails to yield evidence of an underlying humorally mediated cause.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6426577      PMCID: PMC1441018          DOI: 10.1136/bmj.288.6428.1405

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  15 in total

1.  Hypercalcemia in neoplastic disease.

Authors:  W P MYERS
Journal:  Arch Surg       Date:  1960-02

2.  Hyperparathyroidism associated with malignant tumors of nonparathyroid origin.

Authors:  G S Omenn; S I Roth; W H Baker
Journal:  Cancer       Date:  1969-11       Impact factor: 6.860

Review 3.  The relation between serum calcium and tumor metastases.

Authors:  B Gardner
Journal:  Surg Gynecol Obstet       Date:  1969-02

Review 4.  Pseudohyperparathyroidism.

Authors:  F W Lafferty
Journal:  Medicine (Baltimore)       Date:  1966-05       Impact factor: 1.889

5.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

Authors:  A F Stewart; R Horst; L J Deftos; E C Cadman; R Lang; A E Broadus
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

6.  Rehydration in the treatment of severe hypercalcaemia.

Authors:  D J Hosking; A Cowley; C A Bucknall
Journal:  Q J Med       Date:  1981

7.  Predictive value of derived calcium figures based on the measurement of ionised calcium.

Authors:  M D Gardner; F J Dryburgh; J A Fyffe; A S Jenkins
Journal:  Ann Clin Biochem       Date:  1981-03       Impact factor: 2.057

8.  The application of the 99Tcm phosphate bone scan to the study of breast cancer.

Authors:  D L Citrin; R G Bessent; W R Greig; N J McKellar; C Furnival; L H Blumgart
Journal:  Br J Surg       Date:  1975-03       Impact factor: 6.939

9.  Mechanisms of hypercalcemia in malignancy.

Authors:  A Besarab; J F Caro
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

10.  Calcium metabolism in cancer. Studies using calcium isotopes and immunoassays for parathyroid hormone and calcitonin.

Authors:  R S Coombes; M K Ward; P B Greenberg; C J Hillyard; B R Tulloch; R Morrison; G F Joplin
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

View more
  18 in total

Review 1.  Hypercalcemia of malignancy.

Authors:  V Grill; T J Martin
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

Review 2.  1,25-Dihydroxyvitamin D-related hypercalcemia in lymphoma: two case reports.

Authors:  J P Devogelaer; M Lambert; B Boland; C Godfraind; H Noel; C Nagant de Deuxchaisnes
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

3.  Renal handling of calcium and sodium in metastatic and non-metastatic malignancy.

Authors:  S R Heller; D J Hosking
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

4.  Tumor products and the hypercalcemia of malignancy.

Authors:  G R Mundy; K J Ibbotson; S M D'Souza
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

5.  Hypercalcaemia in malignancy.

Authors:  S H Ralston; S J Gallacher; U Parel; I T Boyle
Journal:  BMJ       Date:  1989-07-15

6.  Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence.

Authors:  M S Soyfoo; K Brenner; M Paesmans; J J Body
Journal:  Support Care Cancer       Date:  2012-12-11       Impact factor: 3.603

Review 7.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

8.  Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate.

Authors:  T T Tan; A A Alzaid; N Sutcliffe; M D Gardner; J A Thomson; I T Boyle
Journal:  Postgrad Med J       Date:  1988-03       Impact factor: 2.401

9.  Mechanism of malignant hypercalcaemia in carcinoma of the breast.

Authors:  R C Percival; A J Yates; R E Gray; J Galloway; K Rogers; F E Neal; J A Kanis
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-21

10.  Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry.

Authors:  P D Delmas; B Demiaux; L Malaval; M C Chapuy; C Edouard; P J Meunier
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.